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Models generally consider risk to be a function of the hazard (toxicity) and exposure (dose). That function is best described by the dose response of
the toxic effect. For any risk assessment system to be effective, it should consider that dose-response relationship. Saturation phenomena often
produce nonlinear dose curves, and any risk assessment system should be able to address such effects. Physiologically based pharmacokinetics
offer an approach to deal with these nonlinear responses. Some historic risk models and common saturable processes are discussed. The impact of
maximum tolerated dose (MTD) on risk evaluation and the kinetics of some saturable processes are considered. Specific examples have been
selected to demonstrate the importance of saturation of processes in assessing the hazard of chemicals. - Environ Health Perspect 102(Suppl
11):13-22 (1994)
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Introduction
Risk assessment is an integral part of the
regulation of synthetic chemicals in the
United States. If the process is used prop-
erly, it helps define whether the benefits of
a particular chemical outweigh the risks it
might pose to society. Therefore, it is
imperative that we develop and use the best
methodologies available to assess risk. The
impact of underestimating risk is often
considered. However, if we overestimate
risk, we can precipita-te equally tragic
results, particularly if the action impacts
the prices of essential commodities such as
food. Nearly 25 million people in the
United States live below the poverty level.
They spend more than one-third of their
incomes on food.
The poor already suffer increased mor-
bidity and mortality (1). If we overregulate
and deprive society of useful chemicals,
such as a pesticide that helps improve crop
yield and quality, we could force an
increase in food prices and exacerbate the
nutritional problems of people below the
poverty level.
Therefore, it is important to find risk
assessment systems that consider potency,
This paper was presented at the Workshop on
Pharmacokinetics: Defining Dosimetry for Risk
Assessment held 4-5 March 1992 at the National
Academy of Sciences in Washington, DC.
Address correspondence to Dr. J.T. Stevens,
CIBA-GEIGY Corporation, Agricultural Division, PO
Box 18300, Greensboro, NC 27419. Telephone (910)
632-2158. Fax (910) 632-2997.
not just potential hazard. With increased
awareness of nonlinear processes in biol-
ogy, and the importance ofthese processes
in the dose-response relationships, we
must strive to develop models and
approaches that embrace pharmaco- or bio-
kinetics whenever appropriate.
The use of the linearized multistage
(LMS) model (2), the model currently
used as a default technique by the U.S.
Environmental Protection Agency (U.S.
EPA) (3), does not provide an adequate
assessment of carcinogenic risk. It has
become increasingly evident that the LMS
model in many cases clearly overestimates
risk. However, it is not well recognized that
the LMS model in some instances may
underestimate risk (4,5). Despite either
scenario, it is clear that the model fails to
distinguish adequately between compounds
ofdifferent potencies (6). To the extent
that pharmacokinetics modeling will
improve risk assessment, it must be added
to the tool chest of better understanding.
Application of pharmacokinetic principles
for all chemicals will most certainly be
inappropriate for assessing the risk associ-
ated with all chemicals; however, when
applicable, it can be invaluable.
Any useful system of risk assessment
must be able to properly assess the risk
posed by compounds with different shapes
ofdose-response curves. Compounds that
have exponential and higher order
dose-response curves are less hazardous at
low doses than those with linear or one-hit
type dose responses. If a risk assessment
process does not distinguish dose response
or potency, it can result in risk manage-
ment that will be inappropriate. For exam-
ple, the Federal Insecticide, Fungicide and
Rodenticide Act (FIFRA) forbids "mis-
branding" of pesticides (7); if a product
that does not fit the criteria to be labeled
with DANGER, it cannot carry the DAN-
GER signal word. The proliferation of
unjustified DANGER labels would erode
the significance ofthis hazard classification.
Similarly, carcinogens should be classified
in a fashion that legitimately considers the
dose-response relationships. In this man-
ner we can ensure that the classification
(risk assessment) is not devaluated, and
that the more hazardous materials are
properly identified.
We will attempt to illustrate nonlinear
oncogenic processes with several chemicals
that, during their biokinetic processing,
demonstrate saturation of biochemical
processes or depletion ofcritical cofactors.
Risk assessment of most of these agents
may be improved by using pharmaco-
kinetics; however, some will not benefit.
Indeed, each chemical represents a
challenge to develop and use the most
appropriate risk assessment procedures to
properly address the character of the dose
response.
To address saturable processes and dis-
cuss examples of nonlinear risk relation-
ships, it is appropriate to consider several
areas relative to risk assessment. We briefly
review some early risk models and their
bases, the concept of maximum tolerated
dose (MTD) as a saturation phenomenon
itself,. some biochemical processes and,
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Figure 1. An integrated diagram ofthe toxicologic process.
finally, some old and new examples of
compounds which show these effects.
Discussion
Risk assessment is the actual integration of
hazard, dose response, and exposure infor-
mation into a useful tool for limiting
human exposure to acceptable levels. This
is not as simple as sometimes portrayed
with the application ofthe LMS model (2)
to the hazard data to derive a Qj* value
because the LMS model fails to capture the
integrity of the dose response. An attempt
to capture the dynamics of the process is
given in Figure 1 (8). The simple product
expression of risk is equal to hazard times
exposure cannot hope to correctly address
the essence ofdose response.
From their infancy, mathematical
models were applied as a means to express
numerically the biological process. Most of
these mathematical models have little foun-
dation in biology. Some models that have
been used for risk assessment illustrate
some of the principles that still need to be
considered. The equations for these theo-
retical models are presented in Table 1.
The one-hit model was developed as
the one-hit theory ofinfectious titration, a
biological impact of multiplying organ-
isms. This was attractive because some
types of radiation effects could be pre-
dicted with it (7). The model essentially
predicts a linear dose-response curve at low
doses asymptotically approaching 100%.
This approach to 100% response is a com-
mon factor among risk models, and we all
know that we seldom see tumor responses
approaching 100% with xenobiotics.
The probit model (as proposed by
Mantel and Bryan) is notable because it is
characteristic ofLD50 or ED50 determina-
tions, or the log dose response (9). This
feature is attractive as a model since it is
experimentally demonstrable; but, of
course, it cannot be demonstrated in the
one-in-a-million range.
If we are to believe Paracelsus' admoni-
tion that the dose makes the poison (15),
then we must consider the processes
CYTOTOXICITy
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HAZARD
involved and whether those processes are
controlled by first-order or zero-order
chemical kinetics. It is from those processes
that we should establish a preference for
linear dose or log-dose considerations.
The multistage model or one of its
derivatives is probably the most commonly
used model today (10). Its popularity may
lie in its apparent capability to deal
through the use ofthe quadratic equation
with nonlinear processes (with sufficient
numbers of dose groups). However, this
feature is lost when the model is simplified
to the LMS model that provides the noto-
rious Q1* value. This variant ofthe multi-
stage model is so simplified that the overall
limitations and uncertainties ofour science
may be lost on the public and the policy
makers.
The Cornfield model was the only
model that attempted to address saturable
(enzymatic) processes in risk assessment
(13). Cornfield's model considers carcino-
gens to be simultaneously and reversibly
activated and detoxified in the animal. The
probability of an oncogenic response is
proportional to the concentration of an
activated toxin/substrate complex; this
requirement is fulfilled when the dose (d)
ofthe toxin is less than or equal to the sub-
strate for detoxification (T). Dr. Cornfield
was still working on this model at the time
ofhis death in 1979. Further work perfect-
ing this model has been very limited.
The extent to which nonlinear dose-
response curves affect low-dose extrapola-
tion is illustrated in a comparison ofa "one
hit" or linear dose-response curve with a
fourth-order curve such as one would see
with saccharin (Figure 2). The curves pre-
sented are Weibull distributions, a model
that also has been proposed, but this is
identical to a multistage model having only
single dose terms (12). The difference
between the two models is particularly evi-
dent at the extreme low end of the expo-
sure curve-exactly where risk assessment
is operating.
Table 1. Contemporary models forquantitative risk estimation: foundation and expression.
Foundation
Statistical Biological Model Expression
Tolerance distribution Log-dose response Mantel-Bryan probit(9) P(d) =0(a++ log0(d))
Relational-dose, latency and risk Weibull (10) P(d) = i-eP-d
Quasi-stochastic Assumes nothreshold; one hit, one tumor One-hit(11) P(d) = i-e kd
(mechanistic) Tumordevelopment requires several stages Multistage(12) P(d) = 1-e -00d02d2 -
Assumes linearity; one hit, one tumor Linearized multistage (2) P(d) = 1-e (%+0jd)
Biokinetics Cornfield (13) P(d) =ktd/((S+ks)kt+ksT]
Mechanistic/distributional Time-to-tumorcombined with a multiple Multistage Weibull (14) P(d) = 1-e(0oiOdO2d .0dn)(t-io)s
step process oftumorformation
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Figure 2. Dose responses for one-hit (upper) and
fourth-order (lower) exponential curves.
In addition to these models, there is a
hybrid model that uses the Weibull model
for correcting for time-to-tumor and the
multistage model to plot the tumor
response. This model, called the multi-
stage-Weibull (14), is used to correct the
projected incidence when an effect on sur-
vival is observed (5).
When considering saturable processes,
one cannot ignore the concept of maxi-
mum tolerated dose (MTD) (16,17). The
MTD, by regulatory definition (18), must
be reached for feeding studies to be valid
for risk assessment (3). However, the regu-
latory MTD, by nature of its alteration of
the homeostasis of the animal, must be
considered a saturating process (19). A
nonlinear dose response ofthe toxic effect
does not always occur at the MTD, but
one must consider such potential effects to
be possible. Timbrell reports in his recent
book that xenobiotic metabolism cannot be
separated from intermediary metabolism
(20). This is perfectly logical and illustrates
that we cannot ignore the physiologic state
of the test animals. By focusing on
processes that could be saturated at the
MTD, one must consider several diverse
options. These would include, but would
not be limited to: a) saturating excretion
mechanisms, b) saturating detoxification
mechanisms, c) overwhelming DNA repair,
d) overwhelming immunosurveillance, e)
exceeding tissue repair capacity, andf)
compromising health (8).
Excretion and detoxification have a
direct effect on the toxins. DNA repair and
immuno-surveillance, as well as tissue
repair and replication, are corrective mech-
anisms that are indirectly compound
related.
In the probit risk model, aswell as classic
pharmacology, xenobiotics are considered
to act on the biological system in first order
chemical processes; this leads to theoretical
and experimental correlations with log-dose
relationships. Current risk models usually
use linear dose response considerations; this
implies that zero-order processes are the
rate limiting step in the toxic response.
Several zero- and first-order processes are
delineated in Table 2. Zero-order processes
include active transport systems such as
tubular reabsorption or gastrointestinal
secretion, DNA repair, resynthesis ofcellu-
lar components, and cellular replication.
First-order processes include metabolic
activation, detoxification, and passive
routes of excretion (which are the most
common). In addition, conjugation includ-
ing cofactor depletion is a concentration-
dependent process. All these processes are
better described bylog-dose considerations.
It is interesting to note that the zero-
order processes are generally the repair and
detoxification mechanisms while activation
and toxic responses are first-order
processes. It is then appropriate to question
whether the use ofa linear response as pre-
sented in the multistage model is appropri-
ate. In general, pharmacokinetic models
use standard kinetic expressions and deal
more appropriately with both zero- and
first-order processes. The integration of
kinetic expressions into the simple risk
models has not been routinely attempted.
This means that the implications that the
use oflinear dose models on the value and
direction of the risk assessment have to be
examined.
Both zero-order and first-order
processes are susceptible to saturation phe-
nomena. It seems appropriate to comment
briefly on some ofthe experimental obser-
vations that suggest nonlinear kinetics.
Understanding these processes in the realm
of the pharmacokinetics is truly an area
that deserves consideration, particularly
with the knowledge that chemicals are
often tested at extremely high levels of
administration in an attempt to achieve the
regulatory MTD. At times it appears in
today's science that basic elements of
descriptive evaluation have been lost from
the database. The application of
physical-chemical properties (21), such as
molecular weight, lipophilicity, and ioniza-
tion potential (Figure 3), as well as the
basic approaches to examination ofabsorp-
tion, distribution, metabolism, and elimi-
nation (ADME) is too often overlooked
when the hazard is evaluated (4,22,23).
Regarding the latter approach, some fea-
tures, ifobserved experimentally, provide
the clues to make a determination in regard
to the nonlinearity ofthe processes. These
include:
elimination cannot be describedbyasingle
exponential process,
Table 2. Zero- and first-order saturable biochemical
processes.
Zero-order processes
Active transport systems: reabsorption, secretion
DNArepair
Macromolecular binding
Resynthesis ofcellular components
Cellularreplication
Solubility
First-order processes
Metabolic activation
Metabolite detoxification
Cofactor depletion
Biliary excretion
Renal excretion
Respiratory excretion
GI diffusion
Figure 3. Features leading to nonlinear Michaelis-
Menten kinetics.
* elimination half-life increases with dose,
* area under the plasma concentration ver-
sus time curve is not proportional to
increasing dose, and
* the composition of excretion products
changes quantitatively with increasing
dose.
Shifts in the exponential process as one
evaluates elimination kinetics suggest that
more complicated processes are involved. If
the elimination half-life increases with
dose, or the area under the curve summarily
shifts when one evaluates plasma concen-
trations, then nonlinear kinetics must be
considered. Finally, if the composition of
excretion products changes qualitatively or
shows dramatic quantitative changes with
increasing dose, one must be suspicious of
nonlinear kinetics.
Examples ofSaturation of
Biochemical Processes and
Cofactor Depletion
Solubility: Predpitation intheKidney
Results inNephrotoxicity
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Chemicals OxalicAcid
Description. Oxalic acid is present in
many plants and vegetables where it occurs
in the cell sap ofthe plant as the potassium
or calcium salt (25). It is also the product
of the metabolism ofmolds. Oxalic acid is
used as an analytic reagent, a general reduc-
ing agent, cleaner, and decolorizer. In addi-
tion, it is the toxic metabolite ofethylene
glycol used in auto antifreeze.
Chemical Properties. Oxalic acid is
soluble in water and has a molecularweight
of90.04.
HOOC-COOH
Structure 1. Oxalic acid
Hazard Profile. Nephrotoxicity.
ADME. Oxalic acid is rapidly excreted
by the kidney. At dose levels below the sol-
ubility ofthe calcium salt, appreciable toxi-
city has not been observed (26). The
nonlinearity of the toxicity of oxalate is
illustrated by the physiologic processes
which occur with precipitation. Physio-
logically, calcium oxalate crystals in kidney
tubules cause mechanical damage and
increased liquid pressure. Increasing
intratubular pressure leads to diminished
glomerular filtration and renal blood flow.
The resulting ischemia increases loss of
renal cells.
A proper system ofrisk assessment must
be able to distinguish the dose response of
materials like oxalic acid. The incorpora-
tion ofpharmacokinetic principles into a
risk assessment model offer that distinction
precisely.
Solubilitr. Fonnation ofBladder
CalculiResulting inTumor Formation
Chemicak Melamine
Description. Melamine is a triamino-s-tri-
azine used as synthetic resin used to coat
paper and paper products, as well as to
make tableware (27).
Chemical Properties. Melamine is
slightly soluble in water and insoluble in
ether. The molecular weight ofmelamine is
126.13.
NH2
N
N
H2N NH2
Structure 2. Melamine
Hazard Profile. Melamine is a carcino-
gen in the rat and operates by a mechanism
not dissimilar to calcium oxalate. Melamine
produces bladder carcinomas in rodents
(28).
ADME. Melamine is excreted
unchanged by the kidney; but, when the
concentration in the bladder reaches
sufficient levels, the melamine precipitates
to form calculi. These calculi roll around in
the bladder and the resulting mechanical
irritation results in the tumorigenic
response. In the absence of calculi no
tumors are formed.
One may argue that the mechanism is
known and it is therefore unnecessary to
use mathematical risk assessment with
melamine. However, a proper risk assess-
ment process should be able to recognize
such a dose-response relationship, and that
is better recognized with pharmacokinetic
approaches than with the LMS model.
Saturation ofAbsorption Kinetics at
High Levels ofAdnistration
Chemicals Simazine
Description. Simazine is a symmetrical
chlorotriazine herbicide used in agriculture
for broadleaf-weed control. The mecha-
nism for its herbicidal activity is inhibition
ofphotosynthesis.
Chemical Properties. Simazine is rela-
tively insoluble in water (3.5 ppm) and has
a Log P value of4.18. Its molecular weight
is 201.7.
C1
N N
H3CH2CHN N NHCH2CH3
Structure 3. Simazine
Hazard Profile. Simazine is a triazine
herbicide with low acute mammalian toxic-
ity. The LD50 is about 5 g/kg, while table
salt is about 4 g/kg. The triazine herbicides
inhibit photosynthesis, so it is not surpris-
ing that organisms that do not perform
photosynthesis are not particularly suscep-
tible. Simazine is not a mutagen nor a car-
cinogen in mice or male rats, but it does
produce an increased incidence of mam-
mary tumors in female Sprague-Dawley
rats (29).
ADME. Simazine is rapidly metabo-
lized by dealkylation and glutathione con-
jugation at the ring chloride. Its excretory
distribution changes with dose as depicted
in Figure 4. This response is relevant to
this discussion. Simazine, when adminis-
tered in low doses, is primarily excreted in
the urine with little excreted in the feces.
At higher doses the urinary excretion is
diminished and an approximately 50/50
ratio is found in the urine and feces. In-
terestingly, simazine has a water solubility
Figure 4. Dose-dependent elimination of simazine single
dose (po) to female rats.
of3 ppm. This is ofcourse sufficient to be
absorbed, but may reflect distribution char-
acteristics preventing complete absorption
from the intestine or increased biliary
excretion.
AlteredMetabolism atHigh Levels of
Administration
Chemical Primisu(fiiron
Description. Primisulfuron is a sulfonyl-
urea herbicide used for selected weed con-
trol in corn. Its use rate is in the order of
10 to 20 g/acre.
Chemical Properties. Primisulfuron is
moderately soluble in water (23 ppm). It
has a LogPvalue of 1.15 and apKaof5.1.
Primisulfuron has a molecular weight of
468.3, making it a candidate for biliary
secretion.
0 OCHF2
<$O2/CK N °B coit ClsoiAHN A"M NQ
Structure 4. Primisulfuron
Hazard Profile. This product is not
particularly acutely toxic; it is not a muta-
gen, a teratogen, or a reproductive toxin.
Primisulfuron is not tumorigenic to rats. It
has not been demonstrated to be a poten-
tial oncogen, but at doses above the MTD,
liver tumors were seen in mice (30).
ADME. At doses below the MTD, the
compound is metabolized by hydrolysis of
the sulfonylurea and oxidation, as well as
by conjugation. Feeding levels above 3000
ppm showed a new feces metabolite in
mice. This compound seems to demon-
strate activation ofa secondary pathway of
degradation at these high doses.
A histogram of the chromatography of
the radioactive fecal metabolites of
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Figure 5. Radiochromatograms of primisulfuron
metabolites in the feces of male mice dosed orally.
primisulfuron is presented in Figure 5.
This histogram shows that early eluting
metabolites may change quantitatively with
increasing dose but that the late eluting
metabolite appears only at high doses.
Interestingly this late peak, eluting at frac-
tion 36, seems to be less polar than the par-
ent that elutes at fraction 28 in this
reverse-phase column. It is further interest-
ing to note that the metabolite seems to
form only after repeat dosing, not with a
single dose. The metabolite was identified
after feeding mice radiolabeled primisul-
furon for 28 days.
The structure of the unique high-dose
metabolite is given in Figure 6. The high-
dose metabolite was found to be a dimer of
the original compound with a ring
difluoromethoxy group replaced with a
disulfide bridge between two molecules of
the test material (T Capps, personal com-
munication). The difluoromethoxy groups
remain intact in other metabolites isolated
from mice or rats. This suggests that the
pathway is unique at these high doses. The
presence of the disulfide bridge indicates
that a sulfur-containing cofactor must have
been involved. This presents possibilities
that glutathione conjugation is one of the
intermediate steps and its depletion could
be involved in the toxic response. The
disulfide could be formed in the liver or
the gastrointestinal tract. If it is formed in
the liver (we have not yet tried to cannulate
OOH HOOC
NH NH l~ l
C=0
I N N I
HN S-S
OCHF, OCHF2
Figure 6. Primisulfuron: high feeding level metabolite.
It is clear that fluoride is lost in the fecal metabolite
formation ofthe dimer.
the mouse bile ducts in subchronic feeding
studies), the formation ofa dimer dictates
that second-order chemical kinetics must
describe the reaction. If this were true, a
log-dose response would not be appropri-
ate to describe this material since it would
require an exponent of higher power to
describe the response.
The identification of this metabolite
provides insight to understanding the toxi-
cologic response of fluorosis observed at
levels above 3000 ppm (Figure 6).
Saturation orInhibition ofActive
Transport
Chemicals Sulfinpyrazone
Description. Sulfinpyrazone is a pharma-
ceutical agent that is indicated for the
treatment ofgout. It is a uricosuric agent.
Chemical Properties. Sulfinpyrazone
is a strong organic acid with a pK of2.8.
It is rather soluble in water and has a mole-
cularweight of404.7.
0 N
0 SCH2CH2
Structure 5. Sulfinpyrazone
Hazard Profile. Sulfinpyrazone belongs
to the pyrozole class of agents. There are
inconclusive results in animals suggesting
sulfinpyrazone may be teratogenic. It has
been shown to produce gastrointestinal
irritation in some patients.
ADME. In a discussion ofsaturation in
metabolism it is obligatory to present an
inhibitor of renal tubular reabsorption.
The half-life following intravenous adminis-
tration is 4 hr. Sulfinpyrazone is an example
of a compound that uses its ability to
inhibit the pharmacokinetic process to
achieve the therapeutic objective (32). Any
risk assessment process should be able to
properly consider the nonlinear processes
produced by inhibition ofreabsorption or
secretion.
ReactiveMeabolites
Chemical. Vinyl Chloride
Description. Vinyl chloride has been used
as a chemical intermediate in plastics, as a
refrigerant, and in organic synthesis.
Chemical Properties. Vinyl chloride is
a colorless gas with a molecular weight of
62.5. It is sparsely soluble in water (2.5
ppm at 25°C).
Cc=
H C1
Structure 6. Vinyl chloride.
Hazard Profile. Vinyl chloride is a
human oncogen that has been rather thor-
oughly investigated in regard to its onco-
genic dose response and metabolism (33).
The compound produces angiosarcomas in
humans exposed to high levels.
ADME. Vinyl chloride is metabolically
activated by epoxidation ofthe vinyl group
to produce an epoxide which opens to a
reactive species, probably a carbonium ion
(34). Gehring et al. (35) investigated the
metabolism and kinetics ofvinyl chloride
in rats (Table 3). It was observed that when
the incidence of tumors in rats was com-
pared with the amount ofvinyl chloride
metabolized, a reasonable correlation
was found (36). Metabolic production
plateaued about 2500 ppm (37). Tumor
incidence also seemed to plateau in about
the same area (Table 4). The multistage
model can be used to predict the incidence
of tumors using the dose or using the
amount ofmaterial metabolized (Table 5).
This exercise is essentially the fitting ofthe
dose-response curve to the maximum likeli-
hood estimator ofthe model. As can be seen
the predicted incidence, thus the fit ofthe
curve, is much betterwith the kinetic data.
Table 3. Kinetics ofvinyl chloride metabolism in rats.a
V= VmS/lKm+S)
Michaelis-Menten-type kinetics
V=velocity ofthe biotransformation
ofVC, pg/day
where Vm = 5706 pg VC/4 hr
S = 2.56 pg/ppm/l x ppm exposure
Km = 860 pg/l
aFrom Gehring et al. (34).
Table 4. Calculated production of metabolites of vinyl
chloride in rats.
Exposure, Amount Observed
ppm metabolized, pg/daya incidence, %b
10,000 5,321 14.8
6,000 5,403 21.7
2,500 5,030 22.0
500 3,413 11.9
250 2,435 6.8
50 739 1.7
aFrom Gehring et al. (34). bFrom Maltoni and Lefemine
(35).
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Table 5. A comparison ofthe predicted versus observed
incidences of angiosarcomas in rats exposed to vinyl
chloride.
Multistage model
Incidence
Predicted Predicted
Exposure Observed (dose) (kinetics)
6,000 21.7 26.1 22.8
2,500 22.0 11.9 20.6
500 11.9 2.5 11.7
250 6.8 1.3 7.3
50 1.7 0.3 1.6
CofactorDepletion
ChemicakAcetaminophen
Description. Acetaminophen is an anal-
gesic agent that is sold over the counter.
Chemical Properties. Aceaminophen
is a weak acid which is only slightly soluble
in water. Its molecular weight is 151.2.
Structure 7. Acetaminophen
Hazard Profile. Acute overdosage can
lead to hepatic centrilobular necrosis and,
ifdosage is sufficient, to fatal hepatotoxic-
ity. Renal tubular necrosis has also been
noted (38).
ADME. Acetaminophen is metabolized
primarily by the formation ofglucuronide
and sulfate conjugates. A small amount
may be excreted unchanged and approxi-
mately 4% is converted into a minor
metabolite by the cytochrome oxidase sys-
tem, a quinoneimine (39). This highly
reactive species reacts with glutathione. If
the glutathione is depleted, as is accom-
plished in high doses, it reacts with liver
macromolecules to produce the hepatic
damage.
Chemical. Bromobenzene
Description. Bromobenzene is a solvent
and an additive to motor oils.
Chemical Properties. Bromobenzene is
practically insoluble in water (0.45 ppm)
but miscible in most organic solutions. Its
molecular weight is 157.
Br
Structure 8. Bromobenzene
Hazard Profile. This compound pro-
duces centrilobular hepatic necrosis with
hepatocelluar carcinomas in animals after
prolonged administration. Bromobenzene
is metabolized by epoxidation at the 2,3 or
the 3,4 position (Figure 7). Although pos-
sibly more complex, in general, the 2,3
epoxide leads to 2-bromophenol which
presents the lesser toxicity (40). The 3,4
epoxide may hydrolyze to a phenol or a
diol, or it may react with glutathione. If
glutathione has been depleted, the material
covalently binds to macromolecules in the
liver resulting in the hepatic toxicity (41).
Chemicak Methylene Chloride
Description. Methylene chloride is a solvent
used in degreasing, cleaning agents, and in
food processing.
Chemical Properties. Methylene chlo-
ride is a colorless liquid which has limited
solubility in water (50 ppm at 25°C) and is
miscible with alcohol and ether. It has a
molecular weight of84.94.
CH2C12
Structure 9. Methylene chloride.
Hazard Profile. Methylene chloride
produces hepatocellular adenomas/carcino-
mas in inhalation studies, but not in studies
where the test material is added to water
(42).
ADME. The compound is metabolized
by the hepatic mixed-function oxidase sys-
tem in a saturable process (43). It is also
conjugated with glutathione in an alternative
pathway. Using pharmacokinetic models,
it has been possible to demonstrate that the
liver neoplasia are best correlated with the
glutathione conjugation. The regulatory
risk assessment has been modified to con-
sider that pharmacokinetic process.
Review ofthe metabolism and toxicol-
ogy data (Table 6) indicates that dosage
increases in drinking water produce essen-
tially proportional increases in the amount
Br
Bromobenzene Br
Br / X ,<1 , Covalent binding to
macromolecules
2,3-Oxide 3,4Oxide Glutathione
B
/
J
Br / \ conjugate
tOH [ HOJ
OH
2-Bromophenol 4-Bromophenol 34 OHtyrdo
Figure 7. Metabolism of bromobenzene.
Table 6. Methylene chloride-hepatocellular adeno-
mas/carcinomas in female mice.
Delivered dose
MFO, GST, Tumor
Route Dose g/l/day g/l/day incidence, %
Drinking water, mg/l/day
0 0 0 6
60 1.3 0.003 4
125 2.8 0.007 4
185 4.0 0.011 10
250 5.4 0.016 6
Inhalation, ppm
0 0 0 6
2,000 8.6 0.85 33
4,000 3.7 1.80 83
of material metabolized by both of the
prominent pathways. The tumor data indi-
cate no increase in the background
incidence of tumors at any of the doses
tested. In the inhalation study, the amount
ofmaterial metabolized by the mixed func-
tion oxidases did not change with increas-
ing dose, but conjugated with glutathione
increased proportionally. Tumor incidence
increased with increasing dose. Andersen
and Clewell (44) used physiologically
based pharmacokinetic (PBPK) modeling
studies to demonstrate the effects of this
compound in relation to its metabolism
(Figure 8). They used a PBPK model
which considered separate compartments
for gas exchange and metabolism in the
lung. They, of course, included the usual
distribution in tissues and metabolism in
the liver.
Cellular Replication
Chemical Metolachlor
Description. Metolachlor is a chloroaceta-
nilide herbicide used to control many grass
and broadleafweeds.
Chemical Properties. Metolachlor is
relatively soluble in water (530 ppm at
Figure 8. Physiologically based pharmacokinetic
model for methylene chloride.
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200C) with a Log P = 2.9. Its molecular
weight is 283.8.
CH3
CHCH20CH3
N,
C-CH2C1
Structure 10. Metolachlor
Hazard Profile. Metolachlor is not a
teratogen, a reproductive toxin, or a muta-
gen. Metolachlor produces low increases in
hepatocellular adenomas in female rats at
high doses but not in male rats or mice
(45). In test groups of 70 animals, two
liver adenomas were found in controls and
six primary hepatocellular tumors were
found in animals consuming diets contain-
ing 3000 ppm ofmetolachlor.
ADME. The excretion of metolachlor
is characterized as a complex mixture in
both urine and feces. Multiple metabolites
are observed with no individual metabolite
exceeding a small percentage ofthe admin-
istered dose. Because ofthe hinderance and
stability about the amide nitrogen, there is
virtually no detectable hydrolysis of the
amide. Most of the metabolism occurs
about the chlorine, the methoxy and result-
ing alcohol, and to some extent on the side
chains of the aromatic ring. Considering
the complexities of the metabolic profile,
the urinary excretion of radioactivity was
evaluated and found to fit a first-order,
one-compartment model at high doses
(Figure 9). At lower doses, however, a subtle
shift was observed and a two-compartment
model best fit the data. The limitations on
this process cannot be overemphasized.
The use oftotal radioactivity data does not
allow full consideration ofjust the types of
dose-response changes discussed. Still, the
shift suggested that something had changed
Percentofadministered dose recovered
I.,
0 0.5 1
Dose in mg/kilograms (body weight)
Elimination
Feces
- Urine
Collection time was 168 hours.
Figure 9. High-dose/low-dose renal e.
for rats administered metolachlor.
1.5 2
xcretion curves
in the metabolic process and the homeosta-
sis ofthe animals may be compromised.
In the process of evaluating DNA
repair in vivo, it was observed that there
was an increase in S-phase cells in the livers
ofanimals treated at carcinogenic doses. It
appears from the dose-response curves, the
mutagenicity and the presence of the S-
phase cells in the animal livers, that the
oncogenic response is due to hepatotoxic-
ity. At sufficient doses that result in hepa-
totoxicity, hepatocellular death and
regeneration occur in the rodent liver.
Regeneration ofthe rodent liver is known
to be a promoting phenomenon (46).
This may be due to the fidelity ofreplica-
tion, since partial hepatectomy results in
increased.liver adenomas in rodents.
Binding
Chemial. Saccharin
Description. Saccharin is a noncaloric
sweetener.
Chemical Properties. Saccharin is a
crystalline solid that is highly soluble in
water and in most solvents. It has a molec-
ularweight of183.18.
QNH
s
0 0
Structure 11. Saccharin
Hazard Profile. Saccharin has been
shown to produce bladder carcinomas after
lifetime administration in the diet at 5% or
50,000 ppm (47). This nongenotoxic car-
cinogen binds at high concentrations to
urinary proteins which leads to the forma-
tion ofsilicate-containing precipitate and
microcrystals in the urine of male rats
(48,49). The crystals appear to produce
superficial cytotoxicity to the bladder
epithelium, cell death, and regenerative
hyperplasia. With some diets, no tumor
promotion is observed (50).
ADME. Saccharin is excreted un-
changed in the urine.
The mechanism of tumor formation
has been described as a multistage process
involving binding, chemical reaction, and
cellular mitogenesis. Fortunately the bioas-
say conducted with saccharin uses a
sufficient number offeeding levels to char-
acterize a multistage phenomenon. As a
result, the multistage model predicts that a
curve described by a fourth-order exponen-
tial expression that can be applied to the
data (51), and this yields the best fit
(Figure 10). The curve provides a reason-
N
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Figure 10. Multistage fitforthe rat bladder tumor inci-
dence observed after lifetime administration of sac-
charin.
ably good fit for this model, with a correla-
tion coefficient of >0.95.
These data, along with maximum-like-
lihood-estimate (MLE), are presented in
Table 7. The Qj* is equivalent to the
upper 95% confidence interval for the lin-
ear slope in the linearized multistage
model. At relatively high calculated risks
the MLE and Qj* show a close correlation.
But, at the lower risks (for example, at one-
in-a-million), the difference between the
MLE and Qj* is nearly five orders ofmag-
nitude. Such an observation raises ques-
tions about how the error is calculated. If,
as with most curve-fitting routines, the
error is dependent upon how far the data
points differ from the fitted line, then a
compound that fits the line more closely
would show less error and the calculated
Qj* be less severe. Ifsuch an event were to
occur, it could result in the prediction of
greater risk for a nonlinear compound such
as saccharin than for a compound which
better fits the LMS model.
Honnesis:AParadoxical Response at
Low-DoseLevels
Chemicak Propiconazole
Description. Propiconazole is a broad
spectrum systemic, triazole fungicide that is
used in agriculture for treatment ofdisease
in wheat and rice.
Table 7. Comparison of Q* and best fit (MLE) of the
dose response. For saccharin: P(d) = l-e °O+Qld+Q2d2
where: Qo, = = Q2 =Q3 =0 and Q4 = 8.37x 105.
Calculated risk Bestfit, ppm Q*(2 x 10 ), ppm
10-' 59,600 50,000
10-2 33,000 5000
10-3 18,500 500
10-4 10,500 50
10-5 5,900 5.0
106 3,300 0.5
10-7 1,900 0.05
104 1,100 0.005
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P(d) = I-eQ,8QId Q d I
Where: Q.= Q, =Q2=Q, =0
Q, = 8.37 X IO'S
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Chemical Properties. Propiconazole is
a viscous liquid. It has a solubility in water
of 1 0 ppm (at 20°C). It has a Log P value
of3.3 and a molecular weight of342.22.
Structure 12. Propiconazole
Hazard Profile. The product is not
mutagenic, teratogenic, or tumorigenic in
rats or female mice. There was an increase
in the incidence ofliver tumors observed in
male mice fed propiconazole at the highest
feeding level of 2500 ppm; there is a
significant reduction in tumor formation at
100 ppm, and no effect at 500 ppm (52).
The feeding level of 2500 ppm greatly
exceeded the MTD, as evidenced by a
reduction in survival, a remarkable reduc-
tion in body weight gain, and severe liver
damage.
ADME. Propiconazole is metabolized
by the hepatic mixed-function oxidase sys-
tem. In the rat and mouse the metabolic
profile is complex. It has been shown that
the male mouse and to a somewhat less
degree the female mouse is capable of
cleaving the dioxalane ring. The execretory
profile for the male mouse at high levels of
administration is nonlinear. This pathway
is less operative in the male rat. In addi-
tion, propiconazole has been shown to be a
phenobarbital-type enzyme-inducing
agent.
This final example speaks to the fact
that quantitative risk assessment, as cur-
rently practiced, using LMS default model,
is a giant step backwards. Figure 11 depicts
four data scenarios. Scenario A provides
the incidence of liver tumors observed in
male mice fed propiconazole; this non-
montonic response is impossible to fit
using the LMS model (2). The beneficial
effect at 100 ppm is thought to be real as
this type of hormesis has been observed
with other compounds exhibiting a similar
biological profile to propiconazole.
Scenarios B, C, and D are hypothetical
examples using the same feeding regimen
but altering the incidence. Scenario B
recreates an example of a more potent
supralinear response where the incidence
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Figure 11. Different dose-response relationships: propiconazole and hypothetical scenarios.
noted at 100 and 500 ppm is identical to
that seen at 2500 ppm. This dose response
should yield a large Q1* value for the worst
case. Scenario C sets the 100 and 500 ppm
equivalent to the control value. Finally,
Scenario D leaves the incidence at 2500
ppm fixed and projects a straight line back
through zero, or a linearized response.
The data presented in each scenario are
evaluated. Table 8 presents the estimated
Q1*, the EPA version of the LMS model
(2), and a second version of the LMS
model, a quantal model developed by
Sielken (53). The Sielken LMS is used in
two modes. One mode is essentially
configured to emulate the EPA version; the
second mode is not so constrained so that
it can fit the dose response. It can be seen
that, regardless of the dose response, the
EPA version ofthe LMS yielded essentially
the same Q1* value for all four
dose-response scenarios. On the other
hand, the Sielken unconstrained LMS ver-
sion yielded conservative Q_ * values in the
case of the more severe data sets and less
conservative in the case of the propicona-
zole. Even the Sielken constrained LMS
better reflected the dose response than did
the EPA default model.
Conclusions
Risk assessment has the potential to pro-
vide a useful communication tool. Perhaps,
like the ideal gas laws, we know they are not
accurate, but they still are useful. Risk assess-
ment needs to be as accurate as possible.
Therefore, considering dose response,
pharmacokinetic modeling may provide a
mechanism to improve the accuracy in
many cases. In the past decade there have
been attempts to simplify the complex
process ofrisk assessment to an extrapola-
tion to a single estimator, the Qi*. This
overly simplistic approach has provided a
Table 8. Q1* estimatesa for the linearized multi-stage model, unconstrained and constrained versions of Sielken
(54) and the same constrained model of Crump and Howe (2).
Sielken (54)
Scenario Data Unconstrained Constrained Crump and Howe (2)
A Actual propiconazole 2.7x10-7 3.4x 10-2 5.0x10-2
B Supra linear, 1.1 5.9xlO-1 4.6x 10-2
low- and-mid-levels
set to high-level incidence
C Supra linear, 2.8x 10 2.6x101 4.6x1lY-
low- and mid-levels
set to control incidence
D Linear, 4.7x10-2 4.1 xlO-2 5.x 10-2
control, low- and mid-levels
set to straight line to high-level
BQ1* values expressed in 1/mg/kg/day human equivalent doses.
Environmental Health Perspectives 20INFLUENCE OFSATURATION
haven ofreassurance for everyone who does
not understand its limitations.
This naive approach has not only cre-
ated questionable science, but it has also
created significant cost, both economically
and in terms ofthe public trust. One may
even raise questions concerning the impact
of this approach, which is not used in the
rest of the industrialized world, on the
competitiveness of the United States. Can
our nation afford such harmful extrava-
gance? We think not: let us move forward
and put our mistakes behind us. It is time
to reexamine the biology and chemistry
that is masked behind the endpoint ofhaz-
ard, and to make the process as accurate as
possible. After all, we all know it is indeed
the dose that makes the poison.
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